Lactobacillus improves bloating symptomsProbiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the symptoms of bloating in patients with functional bowel disorders: a double-blind study.
Relevance score indicates significant findings
We conducted a double-blind, placebo-controlled trial to assess how Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 affect bloating in patients with functional bowel disorders.
Over eight weeks, patients reported a noticeable improvement in abdominal bloating when taking probiotics compared to those on a placebo.
Notably, results showed significant relief at four weeks and continued improvement by eight weeks, especially among those with irritable bowel syndrome. This suggests probiotics could be beneficial in managing bloating symptoms.
Read More
SCM-III improves IBS symptomsSingle-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome.
49% relevance, clinically significant
We conducted a study examining the effects of a novel symbiotic treatment, SCM-III, on patients with irritable bowel syndrome (IBS). Sixty-eight adults were divided into two groups—one received SCM-III and the other a heat-inactivated version, both for 12 weeks.
Our findings showed that most patients reported significant improvements in bloating and abdominal pain compared to a control group. Over 80% felt the treatment was effective, while less than 5% labelled it ineffective.
Overall, this suggests that certain IBS patients could greatly benefit from symbiotic treatments like SCM-III, though it may require a cyclic use for best results.
Read More
We examined how Lactobacillus acidophilus can help treat bloating in patients with dyspepsia due to imbalances in gut bacteria. In a study involving 30 participants, symptoms such as pain, pressure, and bloating were self-reported while objective measures like bowel movements and weight changes were also tracked.
Those affected by antibiotic-induced dysbiosis experienced rapid relief within days. Improvements were noted in symptoms of maldigestion over a week, and remarkable results were observed in patients with radiation enterocolitis. Overall, this probiotic showed promise for alleviating digestive discomfort without notable side effects.
Read More
Probiotics reduce IBS-D symptomsA randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live CECT 7347 (ES1) and heat-treated CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome.
Strong evidence of efficacy
We conducted a rigorous study to see how probiotic CECT 7347 (ES1) and its heat-treated version (HT-ES1) could help adults with diarrhea-predominant irritable bowel syndrome (IBS-D).
With 200 participants, we divided them into three groups, administering either the probiotic, the heat-treated version, or a placebo over 12 weeks.
Both ES1 and HT-ES1 showed significant improvements in symptom severity compared to placebo, making them promising options for those seeking relief from IBS-D symptoms.
Read More
We examined the impact of Bifidobacterium longum BB536 combined with Lactobacillus rhamnosus HN001 on bloating in individuals with irritable bowel syndrome (IBS). In a controlled trial with 25 participants, we found that those treated with this probiotic formulation experienced a significant reduction in bloating, with a 36.35% decrease compared to an increase of 7.35% in the placebo group.
The treatment also led to improvements in abdominal pain and overall disease severity, pointing to its potential as an effective therapy for IBS symptoms.
Read More